Holly B. Krasa

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst et al. · New England Journal of Medicine · 2012 · 1.5K citations · Full text

Prevalence of autosomal dominant polycystic kidney disease in the European Union

Cynthia Willey, Jaime D. Blais, Anthony K Hall et al. · Nephrology Dialysis Transplantation · 2016 · 237 citations · Full text

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

Paul B. Watkins, James H. Lewis, Neil Kaplowitz et al. · Drug Safety · 2015 · 187 citations · Full text

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction

James E. Udelson, Cesare Orlandi, John Ouyang et al. · Journal of the American College of Cardiology · 2008 · 179 citations

Heart Failure, Cardiovascular Disease, Medicine +10

Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure

John E. Blair, Faı̈ez Zannad, Marvin A. Konstam et al. · Journal of the American College of Cardiology · 2008 · 174 citations

Heart Failure, Structural Heart Disease, Cardiovascular Disease +10